High top-line revenue is a vanity metric if it doesn't translate to profit. By setting a high margin target (e.g., 80%+) and enforcing it through pricing and cost management, you ensure the business is sane and profitable, not just busy.

The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.

The company once invested 13% of revenue in R&D but saw stagnant growth. The issue was that new products were primarily replacing older ones, not creating new markets. This improved profitability but highlighted the need to balance R&D between incremental improvements and true market expansion.

Rather than selling single products, Novonesis designs custom blends or "cocktails" of different enzymes and microbes. This tailor-made approach solves specific customer problems so effectively that it makes the solution highly unique and difficult for competitors to replicate.

A powerful, overlooked competitive moat exists in the "outsourced R&D" model. These companies, like Core Labs in energy or Christian Hansen in food, become so integral to clients' innovation that they command high margins and valuations that appear expensive when viewed only through the lens of their specific industry.

Novonesis' ingredients are critical performance drivers—defining a yogurt's texture or a detergent's cleaning power—but represent only 1-5% of the customer's cost of goods sold. This low-cost, high-impact dynamic creates immense pricing power and customer stickiness.

Instead of setting prices at launch and letting them erode, Novonesis implemented a discipline of having annual conversations about the value their products deliver. This shifted pricing from a 1-2% annual erosion to a 1-2% revenue growth contributor.

The naive view is that lower prices are always better for customers. However, higher prices generate higher margins, which can be reinvested into R&D. This allows the vendor to improve the product much faster, ultimately delivering more value and making the customer better off than with a cheaper, stagnant product.

The CEO frames their total addressable market not by the current biosolutions industry ($60B) but by the entire specialty chemicals market ($1T) they aim to displace. This expansive view drives a fundamentally different growth strategy and ambition for the company.